Mean Age at Baseline (year) |
8.49 (±4.57), range
1.05–20.41 |
Mean Age at Follow-up (year) |
12.33 (±4.89), range 2.60 –
21.61 |
Mean Follow-Up Interval (year) |
3.84 (±2.68), range 1.00 –
14.39 |
Male / Female |
99 (52.9) / 88 (47.1) |
Race |
|
White |
173 (92.5) |
Black or African-American |
7 (3.7) |
Other |
7 (3.7) |
Median household income in community of residence* |
$83,664, range
$34,118–$213,750 |
Histology |
|
Medulloblastoma |
55 (29.4) |
Ependymoma |
42 (22.5) |
Craniopharyngioma |
29 (15.5) |
Glial (astrocytoma; glioma) |
27 (14.4) |
Germ cell |
16 (8.6) |
Other |
18 (9.6) |
Primary Tumor Location |
|
Infratentorial |
95 (50.8) |
Supratentorial |
92 (49.2) |
Hydrocephalus at diagnosis |
|
Yes |
83 (44.4) |
No |
104 (55.6) |
Radiation Field |
|
Craniospinal |
69 (36.9) |
Focal |
118 (63.1) |
Surgery (before proton radiation)† |
|
Gross total resection |
105 (56.1) |
Near/subtotal resection |
54 (28.9) |
Biopsy |
16 (8.6) |
None |
12 (6.4) |
Chemotherapy treatment (yes) |
121 (64.7) |